DCT

2:26-cv-11583

Organon LLC v. Natco Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-11583, D.N.J., 09/08/2026
  • Venue Allegations: Venue is alleged to be proper based on Defendant Natco USA LLC residing in the district, and all Defendants having committed or intending to commit acts of infringement in the district and maintaining a regular and established place of business there.
  • Core Dispute: Plaintiffs allege that Defendants’ filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs’ VTAMA® (tapinarof) cream infringes nine U.S. patents covering the drug’s composition, manufacturing process, and methods of use.
  • Technical Context: The dispute centers on formulations of tapinarof, an aryl hydrocarbon receptor agonist used for the topical treatment of plaque psoriasis and atopic dermatitis, common inflammatory skin conditions.
  • Key Procedural History: During prosecution of U.S. Patent No. 11,590,088, Plaintiff Dermavant disclaimed several claims, which are noted as not being asserted in this action; this disclaimer may inform the scope of the remaining asserted claims of the '088 patent.

Case Timeline

Date Event
2015-05-21 Earliest Priority Date for ’160, ’743, ’108, ’088 Patents
2017-11-10 Earliest Priority Date for ’649, ’692 Patents
2019-02-05 U.S. Patent No. 10,195,160 Issues
2019-10-01 U.S. Patent No. 10,426,743 Issues
2020-05-12 U.S. Patent No. 10,647,649 Issues
2022-05-23 VTAMA receives FDA approval for plaque psoriasis
2022-10-04 U.S. Patent No. 11,458,108 Issues
2023-02-28 U.S. Patent No. 11,590,088 Issues
2023-03-07 U.S. Patent No. 11,597,692 Issues
2023-03-28 U.S. Patent No. 11,612,573 Issues
2023-04-04 U.S. Patent No. 11,617,724 Issues
2023-04-11 U.S. Patent No. 11,622,945 Issues
2024-12-12 VTAMA receives FDA approval for atopic dermatitis
2025-01-28 Plaintiff Dermavant disclaims claims of the ’088 Patent
2026-07-23 Natco sends ANDA Notice Letter to Organon
2026-09-08 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,195,160 (the “’160 Patent”), "Topical pharmaceutical compositions," issued February 5, 2019

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of creating a topical pharmaceutical composition for the active ingredient tapinarof (3,5-Dihydroxy-4-isopropyl-trans-stilbene) that is both physically and chemically stable, as the compound is known to be sensitive to oxidation and photo-degradation (Compl. ¶37; ’160 Patent, col. 1:16-25; ’160 Patent, col. 1:61-64). Previous formulations were prone to creating non-uniform emulsions with "waxy" regions, indicating instability (’160 Patent, Fig. 1).
  • The Patented Solution: The invention is a topical oil-in-water emulsion that achieves stability by solubilizing the tapinarof active ingredient within the oil phase of the composition, rather than having it suspended or in the water phase (’160 Patent, abstract). This formulation is described as "homogeneous," which avoids the physical instability and non-uniformity of prior attempts and allows for effective delivery of the drug into the skin (’160 Patent, col. 2:40-45; ’160 Patent, Fig. 2).
  • Technical Importance: This formulation technology provided a stable, non-irritating, and effective delivery vehicle for tapinarof, enabling its development as a commercial topical treatment for widespread dermatological conditions like psoriasis (Compl. ¶¶34-35; ’160 Patent, col. 1:50-54).

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the ’160 patent (Compl. ¶59). Independent claim 1 is representative:
  • A topical pharmaceutical oil-in-water emulsion composition comprising:
    • 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof in an amount of about 0.05% to about 2% by weight;
    • an oil phase comprising medium chain triglycerides of a carbon length from six to twelve carbons in an amount of about 2% to about 30% by weight;
    • a water phase;
    • a surfactant in an amount of about 1% to about 20% by weight, wherein the surfactant comprises at least one non-ionic emulsifying wax NF; and
    • a dermatologically acceptable excipient selected from the group consisting of an antioxidant, a pH adjusting agent, a chelating agent, a preservative, a co-solvent and combinations thereof;
    • wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is solubilized in the oil phase and is the only active ingredient in the oil phase;
    • wherein the oil phase is substantially free of petrolatum and mineral oil;
    • wherein the oil-in-water emulsion is homogeneous; and
    • wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.
  • The complaint does not explicitly reserve the right to assert dependent claims, but the allegation for "one or more claims" allows for it (Compl. ¶59).

U.S. Patent No. 10,426,743 (the “’743 Patent”), "Topical pharmaceutical compositions," issued October 1, 2019

The Invention Explained

  • Problem Addressed: Similar to the ’160 Patent, the ’743 Patent addresses the difficulty of creating a physically and chemically stable topical formulation for tapinarof, which is prone to degradation and instability in cream bases (’743 Patent, col. 1:21-34; ’743 Patent, col. 1:61-64).
  • The Patented Solution: The patent claims a method of treating inflammatory skin disorders, such as psoriasis, by administering a specific topical oil-in-water emulsion (’743 Patent, claim 1). The composition, like that of the ’160 Patent, is a homogeneous emulsion where the tapinarof is solubilized in an oil phase that is substantially free of petrolatum, ensuring stability and effective skin delivery (’743 Patent, col. 2:50-59; ’743 Patent, Fig. 2).
  • Technical Importance: This claimed method of use provides a new therapeutic option for treating inflammatory skin diseases by applying a stable and effective form of tapinarof, addressing a need for better topical treatments (Compl. ¶34; Compl. ¶37; ’743 Patent, col. 1:50-54).

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the ’743 patent (Compl. ¶66). Independent claim 1 is representative:
  • A method of treating an inflammatory disease or disorder in a patient in need thereof, the method comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition comprising:
    • an effective amount of 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof;
    • an oil phase; a water phase; a surfactant; and an antioxidant;
    • wherein the emulsion composition is homogenous and the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is solubilized in the oil phase.
  • The complaint does not explicitly reserve the right to assert dependent claims (Compl. ¶66).

Multi-Patent Capsules

  • U.S. Patent No. 10,647,649 (“’649 Patent”), “Process for preparing tapinarof,” issued May 12, 2020

    • Technology Synopsis: The patent claims a process for manufacturing tapinarof, focusing on specific chemical synthesis steps (Compl. ¶40). The invention provides a scalable and efficient route for producing the active pharmaceutical ingredient.
    • Asserted Claims: One or more claims are asserted (Compl. ¶73).
    • Accused Features: The manufacture of the tapinarof active ingredient used in Natco's ANDA Product is alleged to infringe (Compl. ¶74).

  • U.S. Patent No. 11,458,108 (“’108 Patent”), “Topical pharmaceutical compositions,” issued October 4, 2022

    • Technology Synopsis: This patent, like the ’160 Patent, claims a topical pharmaceutical composition of tapinarof in a stable, homogeneous oil-in-water emulsion where the active ingredient is solubilized in the oil phase (Compl. ¶41).
    • Asserted Claims: One or more claims are asserted (Compl. ¶80).
    • Accused Features: Natco’s ANDA Product, by seeking to be a bioequivalent generic of VTAMA, is alleged to have the same infringing composition (Compl. ¶¶52, 56, 81).

  • U.S. Patent No. 11,590,088 (“’088 Patent”), “Use of tapinarof for the treatment of chronic plaque psoriasis,” issued February 28, 2023

    • Technology Synopsis: The patent claims a method of using tapinarof to treat chronic plaque psoriasis (Compl. ¶42). This patent protects the specific indication for which VTAMA was first approved.
    • Asserted Claims: One or more of the remaining in-force claims are asserted, following a disclaimer of other claims by the patent owner (Compl. ¶42; Compl. ¶87).
    • Accused Features: Natco’s proposed product label, by copying the instructions from the VTAMA label for treating plaque psoriasis, is alleged to induce infringement of the patented method (Compl. ¶¶57, 88).

  • U.S. Patent No. 11,597,692 (“’692 Patent”), “Process for preparing tapinarof,” issued March 7, 2023

    • Technology Synopsis: Similar to the ’649 Patent, this patent claims a process for manufacturing the tapinarof active pharmaceutical ingredient (Compl. ¶43).
    • Asserted Claims: One or more claims are asserted (Compl. ¶94).
    • Accused Features: The manufacture of the tapinarof active ingredient used in Natco's ANDA Product is alleged to infringe (Compl. ¶95).

  • Additional Patents: The complaint also asserts U.S. Patent Nos. 11,612,573, 11,617,724, and 11,622,945, all titled "Topical pharmaceutical compositions" and alleged to be infringed by the composition of Natco's ANDA Product (Compl. ¶¶44-46; Compl. ¶¶101-120).

III. The Accused Instrumentality

  • Product Identification: Natco’s ANDA Product, which is a generic version of Organon’s VTAMA (tapinarof) cream, 1% (Compl. ¶1). The product is identified by ANDA No. 221670 (Compl. ¶1).
  • Functionality and Market Context:
    • The accused product is a topical cream intended for the treatment of plaque psoriasis (Compl. ¶55). The complaint alleges that by filing its ANDA, Natco has represented to the FDA that its product will have the same active ingredient (tapinarof), dosage form (1% cream), strength, and method of administration as the reference listed drug, VTAMA (Compl. ¶52).
    • The infringement allegation is based on the act of filing the ANDA, which seeks approval for commercial manufacture and sale prior to the expiration of the patents-in-suit (Compl. ¶1). The complaint alleges that to demonstrate bioequivalence for a topical cream, the generic product must have the same physicochemical and structural attributes and an equivalent rate of drug release, which Plaintiffs contend necessitates infringement of the composition patents (Compl. ¶¶55-56).

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

U.S. Patent No. 10,195,160 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical pharmaceutical oil-in-water emulsion composition comprising: 3,5-dihydroxy-4-isopropyl-trans-stilbene... in an amount of about 0.05% to about 2% by weight... Natco's ANDA Product is a 1% tapinarof cream alleged to be bioequivalent to VTAMA. ¶52; ¶55 col. 10:20-25
an oil phase comprising medium chain triglycerides... in an amount of about 2% to about 30% by weight... The ANDA product is alleged to have the same inactive ingredients and physicochemical attributes as the patented VTAMA formulation to achieve bioequivalence. ¶55; ¶56 col. 12:10-14
a water phase; The ANDA product is alleged to be an oil-in-water cream bioequivalent to VTAMA, necessarily containing a water phase. ¶55 col. 12:41-43
a surfactant in an amount of about 1% to about 20% by weight, wherein the surfactant comprises at least one non-ionic emulsifying wax NF; The ANDA product is alleged to have the same inactive ingredients and physicochemical attributes as the patented VTAMA formulation. ¶55; ¶56 col. 13:30-35
wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene... is solubilized in the oil phase and is the only active ingredient... Plaintiffs allege that to be bioequivalent, the ANDA product must have the same structural attributes, including the solubilization state of the active ingredient. ¶56 col. 7:26-34
wherein the oil phase is substantially free of petrolatum and mineral oil; The patented VTAMA formulation is alleged to be free of petrolatum and mineral oil, a characteristic the ANDA product must match to be bioequivalent. ¶56 col. 11:1-4
wherein the oil-in-water emulsion is homogeneous; The ANDA product must be a stable, homogeneous emulsion to gain FDA approval and be bioequivalent to VTAMA. ¶56 col. 2:44-45
and wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns. Plaintiffs allege the ANDA product must have the same physicochemical attributes as VTAMA, including, inferentially, its droplet size distribution. ¶56 col. 59:52-54

U.S. Patent No. 10,426,743 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating an inflammatory disease or disorder in a patient in need thereof, the method comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition... Natco's proposed label for its ANDA product will allegedly instruct patients and doctors to administer the cream to treat plaque psoriasis, an inflammatory disease. ¶55; ¶57 col. 4:25-28
...comprising: an effective amount of 3,5-dihydroxy-4-isopropyl-trans-stilbene... Natco's ANDA Product contains 1% tapinarof. ¶55 col. 1:35-38
...an oil phase; a water phase; a surfactant; and an antioxidant... The ANDA product is alleged to be a bioequivalent oil-in-water emulsion containing the same excipients as VTAMA. ¶55; ¶56 col. 2:40-44
...wherein the emulsion composition is homogenous and the 3,5-dihydroxy-4-isopropyl-trans-stilbene... is solubilized in the oil phase. To achieve bioequivalence, Natco's ANDA Product is alleged to necessarily possess the same structural and stability characteristics as the patented VTAMA formulation. ¶56 col. 2:44-45
  • Identified Points of Contention:
    • Scope Questions: A central question for the composition claims (e.g., in the ’160 Patent) will be whether the range of excipients and concentrations in Natco's ANDA product falls within the scope of the patent claims. For the method claims (e.g., in the ’743 Patent), a question is whether Natco’s proposed label, which is for plaque psoriasis, instructs a method of treating an "inflammatory disease or disorder" as broadly claimed.
    • Technical Questions: The case will likely hinge on the interpretation of "bioequivalence." A key question for the court will be whether the evidence Natco provides to the FDA to prove its product is bioequivalent to VTAMA (e.g., shared physicochemical attributes, drug release rates) is sufficient to also prove, as a matter of law, that it meets the specific structural limitations of the claims, such as "homogeneous" and "solubilized in the oil phase."

V. Key Claim Terms for Construction

  • The Term: "homogeneous"

  • Context and Importance: This term is critical because the patents distinguish the invention from prior unstable formulations that developed "waxy" non-uniform regions (’160 Patent, col. 2:8-12; ’160 Patent, Fig. 1). Practitioners may focus on this term because infringement will depend on whether Natco's product, which must be stable for FDA approval, is considered "homogeneous" as the patent defines it.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patents do not provide a precise definition, which may support an argument for the term's plain and ordinary meaning of being uniform in composition.
    • Evidence for a Narrower Interpretation: The specification explicitly contrasts "homogeneous" compositions with prior art that was "non-uniform" (’160 Patent, Fig. 1; ’160 Patent, Fig. 2). The patents also link homogeneity to specific structural characteristics, such as the active ingredient being "solubilized in the oil phase" and specific average droplet sizes, which could support a narrower definition tied to these technical features (’160 Patent, col. 2:44-45; ’160 Patent, claim 1).

  • The Term: "solubilized in the oil phase"

  • Context and Importance: This limitation is a core technical feature of the patented formulation, presented as the solution to the instability of prior tapinarof compositions (’160 Patent, abstract; ’160 Patent, col. 7:26-34). Whether Natco's product meets this limitation will be a central point of the infringement analysis.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The claims themselves do not quantify the degree of solubilization required, which could support an interpretation that any amount of solubilization meets the limitation.
    • Evidence for a Narrower Interpretation: The specification describes a "preferred embodiment" where "≥95% or ≥98% w/w of the active ingredient is solubilized in the oil phase of the emulsion" (’160 Patent, col. 8:30-34). This language could be used to argue that "solubilized" requires a very high, nearly complete degree of dissolution in the oil phase to achieve the invention's stated benefits.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for the method-of-use patents (e.g., ’743, ’088, ’573 patents) based on the assertion that Natco’s proposed product label will copy the instructions from VTAMA’s label, thereby encouraging and instructing patients and physicians to perform the patented methods (Compl. ¶57; Compl. ¶69; Compl. ¶90; Compl. ¶104). Contributory infringement is alleged for all patents on the basis that Natco’s ANDA Product is a material component especially made for infringing use and not suitable for a substantial non-infringing use (Compl. ¶63; Compl. ¶70).
  • Willful Infringement: The complaint does not contain a formal count for willful infringement. However, it alleges that Natco has had knowledge of the patents-in-suit since at least its notice letter of July 23, 2026, and through the FDA's Orange Book listing (Compl. ¶61; Compl. ¶68). Plaintiffs request a finding that this is an "exceptional case" warranting an award of attorneys' fees, which is a remedy often associated with findings of willful infringement (Compl. ¶121.w).

VII. Analyst’s Conclusion: Key Questions for the Case

  1. A central issue will be one of infringement-by-bioequivalence: Will the technical and clinical data Natco must submit to the FDA to prove its generic cream is bioequivalent to VTAMA also serve as sufficient evidence to prove that it meets the specific, quantitative limitations of the composition claims, such as being "homogeneous" with tapinarof "solubilized in the oil phase"?
  2. A second key question will concern validity and non-obviousness: Given that tapinarof and oil-in-water emulsions were known in the art, can Plaintiffs successfully argue that their specific formulation—a homogeneous emulsion substantially free of petrolatum with the active ingredient solubilized in the oil phase—was a non-obvious solution to the long-felt but unresolved problem of tapinarof's instability in topical creams?
  3. For the method-of-use patents, a dispositive question will be one of induced infringement: Does Natco's proposed product label, by being a copy of the VTAMA label for the treatment of plaque psoriasis, contain affirmative instructions that would lead a fact-finder to conclude Natco possessed the specific intent to encourage direct infringement of the patented treatment methods by patients and physicians?